{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:52:10Z","timestamp":1793962330984,"version":"4.8.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Diagnostics International Ltd"},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017307","name":"NSABP Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ability to predict ovarian function loss after anticancer treatment is important for appropriate oncofertility counseling and to aid in therapy decision-making for young women with early breast cancer (eBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This biomarker analysis of the BETH (NCT00625898) and KAITLIN (NCT01966471) randomized trials investigated anti-M\u00fcllerian hormone (AMH) use, alone and combined with follicle stimulating hormone (FSH) and estradiol (E2), for predicting ovarian function loss following currently adopted chemotherapy and anti-HER2 therapy in premenopausal women with HER2-positive eBC. Serum samples were centrally tested measuring AMH, FSH, and E2 using Roche Elecsys assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 194 included patients (BETH: n\u2009=\u200962; KAITLIN: n\u2009=\u2009132), AMH values declined from baseline median 8.44\u2009pmol\u00a0L\u22121 to undetectable levels (&amp;lt;0.07\u2009pmol\u00a0L\u22121) at the end of therapy, with partial recovery at 36\u2009months (median 0.14\u2009pmol\u00a0L\u22121). AMH measured at baseline was predictive of ovarian loss (area under the ROC curve [AUC]\u2009=\u20090.784). Addition of age to AMH slightly improved AUC to 0.800. AMH measured at the end of therapy had AUC 0.741, which increased to 0.785 with addition of age. The combination of AMH at baseline and end of therapy increased prediction to 0.808 and with addition of age to 0.820. Addition of baseline FSH and E2 did not improve prediction in any analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results support the use of pretreatment measurement of AMH in predicting ovarian function loss in premenopausal women with HER2-positive eBC receiving chemotherapy and anti-HER2 therapy. Measurement of AMH at the end of treatment had reduced accuracy than pretreatment but in combination added slightly to the value of pretreatment sampling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf198","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T11:48:05Z","timestamp":1753444085000},"page":"2317-2326","source":"Crossref","is-referenced-by-count":9,"title":["Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genoa,","place":["Italy"]},{"name":"Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino , Genoa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5838-2887","authenticated-orcid":false,"given":"Deirdre","family":"Allegranza","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Roche Diagnostics International Ltd , Rotkreuz,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruediger P","family":"Laubender","sequence":"additional","affiliation":[{"name":"Biostatistics & Data Science Core Lab & Near Patient Care, Roche Diagnostics GmbH , Penzberg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[{"name":"Breast Center, Department of OB&GYN and CCC Munich, LMU University Hospital , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-3830","authenticated-orcid":false,"given":"Sandra M","family":"Swain","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center, Lombardi Comprehensive Cancer Center , Washington, DC,","place":["United States"]},{"name":"MedStar Health , Washington, DC, z","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2379-5702","authenticated-orcid":false,"given":"Charles E","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Medicine, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-498X","authenticated-orcid":false,"given":"Dennis J","family":"Slamon","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bobba","sequence":"additional","affiliation":[{"name":"Clinical Development and Medical Affairs, Roche Diagnostics International Ltd , Rotkreuz,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Translational Medicine Oncology, F. Hoffmann-La Roche Ltd , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"de Haas","sequence":"additional","affiliation":[{"name":"Translational Medicine Oncology, F. Hoffmann-La Roche Ltd , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5751-094X","authenticated-orcid":false,"given":"Eleonora","family":"Restuccia","sequence":"additional","affiliation":[{"name":"Product Development Oncology, F. Hoffmann-La Roche Ltd , Basel,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-2260","authenticated-orcid":false,"given":"Ines","family":"Vaz-Luis","sequence":"additional","affiliation":[{"name":"Cancer Survivorship Group, Inserm Unit 981, Gustave Roussy , Villejuif,","place":["France"]},{"name":"Department for the Organization of Patient Pathways, Gustave Roussy , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2717-7979","authenticated-orcid":false,"given":"David A","family":"Cameron","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Cancer, Western General Hospital\u2014NHS Lothian , Edinburgh,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-5944","authenticated-orcid":false,"given":"Ian E","family":"Krop","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-1723","authenticated-orcid":false,"given":"Eric P","family":"Winer","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-518X","authenticated-orcid":false,"given":"Richard A","family":"Anderson","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh , Edinburgh,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025110923133751400_djaf198-B1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025110923133751400_djaf198-B2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","article-title":"ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)","volume":"33","author":"Paluch-Shimon","year":"2022","journal-title":"Ann Oncol"},{"key":"2025110923133751400_djaf198-B3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2013.52.8877","article-title":"Prospective study of fertility concerns and preservation strategies in young women with breast cancer","volume":"32","author":"Ruddy","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025110923133751400_djaf198-B4","doi-asserted-by":"crossref","first-page":"690320","DOI":"10.3389\/fonc.2021.690320","article-title":"The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and\/or fertility preservation strategies in premenopausal women with early breast cancer","volume":"11","author":"Blondeaux","year":"2021","journal-title":"Front Oncol"},{"key":"2025110923133751400_djaf198-B5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"key":"2025110923133751400_djaf198-B6","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"ESHRE Guideline Group on Female Fertility Preservation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2025110923133751400_djaf198-B7","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.19.02242","article-title":"Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor-positive breast cancer","volume":"38","author":"Lambertini","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025110923133751400_djaf198-B8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.fertnstert.2009.03.045","article-title":"Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer","volume":"94","author":"Partridge","year":"2010","journal-title":"Fertil Steril"},{"key":"2025110923133751400_djaf198-B9","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.26403","article-title":"Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer","volume":"118","author":"Letourneau","year":"2012","journal-title":"Cancer"},{"key":"2025110923133751400_djaf198-B10","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"key":"2025110923133751400_djaf198-B11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.fertnstert.2015.11.020","article-title":"Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all","volume":"105","author":"Jacobson","year":"2016","journal-title":"Fertil Steril"},{"key":"2025110923133751400_djaf198-B12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.017","article-title":"Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: an ASTRRA study report","volume":"151","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025110923133751400_djaf198-B13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/humupd\/dmt062","article-title":"The physiology and clinical utility of anti-Mullerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2025110923133751400_djaf198-B14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.fertnstert.2023.02.019","article-title":"Contraceptive-specific antim\u00fcllerian hormone values in reproductive-age women: a population study of 42,684 women","volume":"119","author":"Nelson","year":"2023","journal-title":"Fertil Steril"},{"key":"2025110923133751400_djaf198-B15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/humrep\/den480","article-title":"Anti-M\u00fcllerian hormone-based approach to controlled ovarian stimulation for assisted conception","volume":"24","author":"Nelson","year":"2009","journal-title":"Hum Reprod"},{"key":"2025110923133751400_djaf198-B16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/humupd\/dmq034","article-title":"AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis","volume":"17","author":"Broer","year":"2011","journal-title":"Hum Reprod Update"},{"key":"2025110923133751400_djaf198-B17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0015-0282(01)02993-4","article-title":"Antim\u00fcllerian hormone serum levels: a putative marker for ovarian aging","volume":"77","author":"de Vet","year":"2002","journal-title":"Fertil Steril"},{"key":"2025110923133751400_djaf198-B18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/humupd\/dmac045","article-title":"Anti-M\u00fcllerian hormone for the diagnosis and prediction of menopause: a systematic review","volume":"29","author":"Nelson","year":"2023","journal-title":"Hum Reprod Update"},{"key":"2025110923133751400_djaf198-B19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2025110923133751400_djaf198-B20","doi-asserted-by":"crossref","first-page":"e22024","DOI":"10.1371\/journal.pone.0022024","article-title":"A validated model of serum anti-M\u00fcllerian hormone from conception to menopause","volume":"6","author":"Kelsey","year":"2011","journal-title":"PLoS One"},{"key":"2025110923133751400_djaf198-B21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2010-2582","article-title":"Pretreatment serum anti-M\u00fcllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer","volume":"96","author":"Anderson","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025110923133751400_djaf198-B22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.24746","article-title":"Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors","volume":"116","author":"Su","year":"2010","journal-title":"Cancer"},{"key":"2025110923133751400_djaf198-B23","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.ejca.2013.07.014","article-title":"Pretreatment anti-M\u00fcllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer","volume":"49","author":"Anderson","year":"2013","journal-title":"Eur J Cancer"},{"key":"2025110923133751400_djaf198-B24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1634\/theoncologist.2015-0183","article-title":"Predicting ovarian activity in women affected by early breast cancer: a meta-analysis-based nomogram","volume":"20","author":"Barnabei","year":"2015","journal-title":"Oncologist"},{"key":"2025110923133751400_djaf198-B25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","article-title":"The utility of anti-M\u00fcllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer","volume":"87","author":"Anderson","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025110923133751400_djaf198-B26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-021-06508-w","article-title":"Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer","volume":"192","author":"Anderson","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2025110923133751400_djaf198-B27","doi-asserted-by":"crossref","first-page":"S1-03","DOI":"10.1158\/0008-5472.SABCS13-S1-03","article-title":"Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab \u00b1 bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer","volume":"73","author":"Slamon","year":"2013","journal-title":"Cancer Res"},{"key":"2025110923133751400_djaf198-B28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.21.00896","article-title":"Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III KAITLIN study","volume":"40","author":"Krop","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025110923133751400_djaf198-B29","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE guideline: management of women with premature ovarian insufficiency","volume":"31","author":"European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI","year":"2016","journal-title":"Hum Reprod"},{"key":"2025110923133751400_djaf198-B30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/13697137.2020.1804547","article-title":"Premature ovarian insufficiency: an International Menopause Society White Paper","volume":"23","author":"Panay","year":"2020","journal-title":"Climacteric"},{"key":"2025110923133751400_djaf198-B31","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","article-title":"Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement","volume":"24","author":"Cui","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025110923133751400_djaf198-B32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2013.07.007","article-title":"Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer","volume":"89","author":"Torino","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025110923133751400_djaf198-B33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jc.2011-3362","article-title":"Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"97","author":"Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2025110923133751400_djaf198-B34","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.ejca.2014.06.011","article-title":"A highly-sensitive anti-M\u00fcllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer","volume":"50","author":"Chai","year":"2014","journal-title":"Eur J Cancer"},{"key":"2025110923133751400_djaf198-B35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.2013-0145","article-title":"Prediction of postchemotherapy ovarian function using markers of ovarian reserve","volume":"19","author":"Henry","year":"2014","journal-title":"Oncologist"},{"key":"2025110923133751400_djaf198-B36","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/humrep\/deaf096","article-title":"Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies","volume":"40","author":"Arecco","year":"2025","journal-title":"Hum Reprod"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf198\/64029803\/djaf198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2317\/64029803\/djaf198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2317\/64029803\/djaf198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T04:13:48Z","timestamp":1762748028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/11\/2317\/8232744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf198","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,12]]}}}